ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag dna genomics science policy trump

2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Opinion: The Politics of Science and Racism
Sadye Paez and Erich D. Jarvis | Aug 18, 2020 | 7 min read
Race has been used to segment humanity and, by extension, establish and enforce a hierarchy in science. Individual and institutional commitments to racial justice in the sciences must involve political activity.
Genome Investigator Craig Venter Reflects On Turbulent Past And Future Ambitions
Karen Young Kreeger | Jul 23, 1995 | 8 min read
And Future Ambitions Editor's Note: For the past four years, former National Institutes of Health researcher J. Craig Venter has been a major figure in the turbulent debates and scientific discoveries surrounding the study of genes and genomes. Events heated up in 1991, when NIH attempted to patent gene fragments, which were isolated using Venter's expressed sequence tag (EST)/complementary DNA (cDNA) approach for discovering human genes (M.A. Adams et al., Science, 252:1651-6, 1991). NIH's mo
A photo of a skeleton on a black background
Ancient DNA Boom Underlines a Need for Ethical Frameworks
Amanda Heidt | Jan 27, 2022 | 10+ min read
The field of ancient DNA, which combines archaeology and anthropology with cutting-edge genetics, is requiring scientists to have frank conversations about when research is justified and who it benefits.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
Week in Review: February 13–17
Joshua A. Krisch | Feb 16, 2017 | 3 min read
CRISPR patent decision; DNA database errors; science marches around the globe; more
Will Genomics Spoil Gene Ownership?
Douglas Steinberg | Sep 3, 2000 | 8 min read
Consider a scenario for the year 2002: Using commercially available software, bioprospector "Craig Collins" spends a day scavenging the Human Genome Project (HGP) database for the alternatively spliced genes prized by Wall Street. He enters the sequences of several candidate genes into a software package that prints out the likely functions of their protein products. One protein looks like it could be pharmaceutical paydirt, so he isolates the corresponding cDNA, inserts it into a vector, then
Planning the Future of Plant Genomics
Eugene Russo | Jul 21, 2002 | 5 min read
Image: Courtesy of National Sciences Foundation Arabidopsis Plant genomics researchers stand at a crossroads. Behind them are the completed genome sequences of rice1 and the model mustard plant Arabidopsis thaliana.2 Now, armed with insights gained from both plant and animal sequencing projects, plant biologists must decide how to proceed with future sequencing, proteomics, and functional genomics endeavors--and how to allot precious basic research dollars while, at the same time, keeping
Privatizing the Human Genome?
Paul Smaglik | Jun 7, 1998 | 10 min read
Principals behind joint-venture proposal and public effort seek to define relationships A private effort to sequence the human genome four years ahead of the Human Genome Project's 2005 goal could either compete directly with the federal project or meld seamlessly with it. Before any relationship between the two efforts becomes formalized, scientists and federal officials involved with the Human Genome Project must determine whether the private approach will work, who will own the data, how qu

Run a Search

ADVERTISEMENT